Federal reviewer recommends pharmaceutical sales of Cornerstone's low salt drug; Against Approval Of Lixivaptan To Treat Hyponatremia

Federal reviewer recommends pharmaceutical sales of Cornerstone's low salt drug
MedReps
Pharmaceutical sales recruiters are keeping a close eye on Cornerstone Therapeutics after a clinical reviewer recommended that the Food and Drug Administration (FDA) approve the company's new low salt drug, lixivaptan.

Cornerstone (CRTX) Tumbles After FDA Committee Votes Against Hyponatremia ... iStockAnalyst
Cornerstone:FDA Panel Votes Against Approval Of Lixivaptan To Treat Hyponatremia

Restaurant foods for takeout, catering, business meetings, team lunches, conferences, and sporting events.

Translate

Sponsored Links

Recent Additions